Vitamin B12 Test: Levels, Deficiency, and Interpretation

Vitamin B12 (cobalamin) is an essential water-soluble vitamin required for DNA synthesis, red blood cell formation, and the maintenance of the myelin sheath surrounding nerve fibers. Because B12 is found almost exclusively in animal-derived foods and requires a complex absorption process, deficiency is surprisingly common — affecting an estimated 6% of adults under 60 and nearly 20% of those over 60 in developed countries.

Table of Contents

1. Overview
2. When Ordered
3. Reference Ranges
   1. Serum Vitamin B12
   2. Methylmalonic Acid (MMA)
   3. Homocysteine (Cross-Reference)
4. Deficiency Symptoms
5. Causes of Deficiency
6. Functional vs. Conventional Testing
7. Treatment
8. References

Overview

Vitamin B12 is unique among vitamins for two reasons: it requires a specialized carrier protein — intrinsic factor (IF) — for absorption in the terminal ileum, and it is stored in significant quantities in the liver (2–5 mg), providing a reserve that may take 3–5 years to deplete even with complete dietary cessation. This long reserve explains why B12 deficiency often develops insidiously and is diagnosed late.

B12 functions as a cofactor for two key enzymatic reactions:

1. Methionine synthase (with methylcobalamin): converts homocysteine to methionine, linking B12 to folate metabolism and DNA methylation. Deficiency causes elevated homocysteine and impaired myelin synthesis.
2. Methylmalonyl-CoA mutase (with adenosylcobalamin): converts methylmalonyl-CoA to succinyl-CoA in the mitochondria. Deficiency causes elevated methylmalonic acid (MMA) — the most sensitive biochemical marker of functional B12 deficiency.

The absorption pathway is complex: dietary B12 must be released from food protein by gastric acid and pepsin, bound to haptocorrin (R-protein) in the stomach, transferred to intrinsic factor (secreted by gastric parietal cells) in the duodenum after pancreatic enzymes cleave the R-protein, and then absorbed via cubilin receptors in the terminal ileum. Failure at any step causes deficiency.

When Ordered

A vitamin B12 test is ordered when a clinician suspects deficiency based on clinical presentation, risk factors, or findings on a complete blood count (CBC):

• Macrocytic anemia — elevated mean corpuscular volume (MCV >100 fL) on CBC, especially with hypersegmented neutrophils on peripheral smear
• Neurological symptoms — subacute combined degeneration of the spinal cord: paresthesias, numbness, weakness, ataxia, cognitive decline, or psychiatric symptoms
• Elevated homocysteine — found on cardiovascular risk panels; B12 and folate are the most common correctable causes
• Risk factor screening — vegetarian or vegan diet, prior gastric surgery (Roux-en-Y bypass, sleeve gastrectomy), gastric resection, ileal disease (Crohn's disease, ileal resection), pernicious anemia
• Medication review — long-term metformin, proton pump inhibitors (PPIs), H2 blockers, or nitrous oxide exposure
• Age >60 — gastric atrophy reduces intrinsic factor and acid production, impairing food-bound B12 absorption
• Glossitis or angular cheilitis — smooth, beefy-red tongue or mouth sores may indicate B12 or folate deficiency
• Unexplained fatigue, cognitive decline, or depression in the presence of risk factors

Reference Ranges

Serum Vitamin B12

Serum B12 measures total circulating cobalamin. However, approximately 80% of circulating B12 is bound to haptocorrin, a transport protein that carries metabolically inactive B12 analogues. Only about 20% is bound to transcobalamin II (holotranscobalamin), which delivers B12 to cells. This means serum B12 can appear normal even when cellular B12 stores are functionally depleted — a concept known as subclinical or functional deficiency.

Serum Vitamin B12 (pg/mL)

The "low-normal" gray zone (200–300 pg/mL): Many patients with levels in this range have biochemical evidence of functional B12 deficiency (elevated MMA and/or homocysteine) despite being technically within normal limits. Clinicians increasingly treat or further investigate patients in this range who have compatible symptoms.

Clinical notes on elevated B12: A serum B12 above 900 pg/mL, especially without supplementation, may indicate liver disease (hepatic B12 release), myeloproliferative disorders (polycythemia vera, CML — increased haptocorrin production), or solid malignancies. Persistently elevated B12 without an obvious cause warrants further evaluation.

Methylmalonic Acid (MMA)

MMA is the most sensitive and specific functional marker of cellular B12 deficiency. When adenosylcobalamin is depleted within the mitochondria, methylmalonyl-CoA cannot be converted to succinyl-CoA, causing MMA to accumulate in the blood and spill into the urine. MMA remains normal in folate deficiency, making it a key tool for distinguishing B12 from folate deficiency when both are possible.

Serum Methylmalonic Acid (MMA) (µmol/L)

Clinical notes: MMA elevation is highly specific for B12 deficiency (it is not elevated in folate deficiency). It can be elevated in renal insufficiency (reduced urinary excretion), methylmalonyl acidemia (rare inherited disorder), and small intestinal bacterial overgrowth (SIBO). When in doubt, measuring both serum MMA and homocysteine together identifies the vast majority of B12-deficient patients, including those with borderline serum levels. MMA normalizes within weeks of effective B12 repletion, making it useful for confirming treatment response.

Homocysteine (Cross-Reference)

Homocysteine is elevated in both B12 deficiency and folate deficiency, as both vitamins are required for the remethylation of homocysteine to methionine. Elevated homocysteine is an independent risk factor for cardiovascular disease, stroke, deep vein thrombosis, and dementia. Measuring both MMA and homocysteine together provides the highest sensitivity for detecting B12 deficiency.

Total Plasma Homocysteine (µmol/L)

Interpreting the combination: Elevated MMA and elevated homocysteine strongly suggests B12 deficiency. Elevated homocysteine with normal MMA points to folate deficiency, B6 deficiency, or genetic hyperhomocysteinemia (MTHFR polymorphism). Normal MMA and normal homocysteine with low serum B12 suggests spurious low B12 (e.g., from oral contraceptives reducing serum binding proteins) or that the patient has adequate intracellular B12 stores despite low serum levels.

Deficiency Symptoms

B12 deficiency affects two major organ systems: the hematopoietic system and the nervous system. Neurological symptoms can occur even without anemia — making clinical awareness critical.

Hematologic Manifestations

• Macrocytic megaloblastic anemia — large, misshapen red blood cells (macrocytes) result from impaired DNA synthesis. MCV typically exceeds 100 fL and may reach 120–130 fL in severe cases.
• Hypersegmented neutrophils — 5-lobed neutrophils (or any 6-lobed neutrophil) on peripheral blood smear are characteristic of megaloblastic anemia.
• Pancytopenia — in severe cases, all cell lines are reduced: anemia, leukopenia, thrombocytopenia.
• Mild hemolysis — ineffective erythropoiesis in the bone marrow leads to intramedullary destruction of developing red cells, elevating lactate dehydrogenase (LDH) and indirect bilirubin.

Neurological Manifestations (Subacute Combined Degeneration)

• Peripheral neuropathy — symmetric, "stocking-glove" paresthesias (tingling, numbness) beginning in the feet and hands, progressing proximally
• Posterior column dysfunction — loss of vibration sense and proprioception; positive Romberg test; gait ataxia
• Corticospinal tract involvement — weakness, spasticity, hyperreflexia in the legs (late finding)
• Cognitive impairment — memory loss, confusion, dementia, particularly in elderly patients
• Psychiatric symptoms — depression, irritability, psychosis ("megaloblastic madness" in severe cases)
• Optic neuropathy — rare; progressive visual loss from demyelination of the optic nerves

Other Symptoms

• Glossitis — smooth, painful, red tongue (atrophic glossitis)
• Angular cheilitis — cracking at the corners of the mouth
• Fatigue and weakness out of proportion to anemia
• Infertility — impaired DNA synthesis affects gamete production
• Elevated cardiovascular risk from hyperhomocysteinemia

Causes of Deficiency

Pernicious Anemia

Pernicious anemia is an autoimmune condition in which the immune system attacks gastric parietal cells, destroying their ability to produce intrinsic factor. Without intrinsic factor, B12 from food cannot be absorbed in the terminal ileum. It is the most common cause of severe B12 deficiency in the developed world and is associated with other autoimmune diseases (thyroid disease, type 1 diabetes, vitiligo). Diagnosis is confirmed by measuring anti-intrinsic factor antibodies (highly specific, ~50% sensitive) and anti-parietal cell antibodies (less specific). Treatment requires parenteral B12 (intramuscular injections) or high-dose oral B12 (1000 µg/day exploits passive diffusion).

Vegan and Strict Vegetarian Diet

B12 is found almost exclusively in animal products: meat, poultry, seafood, eggs, and dairy. Vegans who do not supplement or consume fortified foods will inevitably become B12 deficient, though the onset may take years due to hepatic stores. Vegetarians who consume dairy and eggs are at lower but still significant risk. Fortified foods (nutritional yeast, plant-based milks, cereals) and B12 supplements are essential for vegans. Breastfed infants of vegan mothers are at high risk of severe B12 deficiency and neurological damage.

Metformin Use

Metformin, the most widely prescribed medication for type 2 diabetes, reduces B12 absorption by approximately 30% through competitive inhibition of the calcium-dependent cubilin receptor in the ileum. B12 deficiency develops in an estimated 5–10% of long-term metformin users, and the risk increases with dose and duration. Screening is recommended every 2–3 years in metformin-treated patients. Calcium supplementation may partially reverse the absorption defect. The American Diabetes Association recommends periodic B12 monitoring for all metformin users.

Proton Pump Inhibitor (PPI) and H2 Blocker Use

Gastric acid is required to cleave B12 from food protein. Long-term acid suppression with PPIs (omeprazole, lansoprazole, pantoprazole) or H2 blockers (famotidine, ranitidine) impairs the first step of B12 absorption from food. Crystalline B12 in supplements is absorbed independently of acid and is not affected. Studies show a 65% increased risk of B12 deficiency with >2 years of PPI use. The effect is dose-dependent and most clinically significant in the elderly, who already have reduced gastric acid secretion from atrophic gastritis.

Gastric Surgery

Roux-en-Y gastric bypass, sleeve gastrectomy, and partial gastrectomy reduce or eliminate the acid-secreting mucosa and the intrinsic factor-producing parietal cells. B12 deficiency is nearly universal after gastric bypass without supplementation, and post-bariatric patients require lifelong high-dose oral or intramuscular B12 supplementation. Total gastrectomy obligates parenteral supplementation.

Ileal Disease and Resection

Crohn's disease, radiation ileitis, or surgical resection of the terminal ileum eliminates the site of B12-intrinsic factor complex absorption. The length of ileum resected or inflamed correlates with the severity of malabsorption. Patients with >60 cm of terminal ileum resected almost invariably require parenteral B12.

Other Causes

• Atrophic gastritis — age-related loss of parietal cells and acid secretion; affects up to 30% of elderly individuals
• Nitrous oxide (N₂O) exposure — anesthetic gas irreversibly oxidizes methylcobalamin, acutely precipitating deficiency in patients with borderline stores
• Tapeworm infection (Diphyllobothrium latum) — competes for dietary B12 in the gut
• SIBO — bacteria consume luminal B12 before absorption
• Transcobalamin II deficiency — rare congenital disorder impairing cellular B12 delivery

Functional vs. Conventional Testing

Conventional medicine typically considers B12 deficiency only when serum levels fall below 200 pg/mL. Functional and integrative medicine practitioners argue that this threshold is too low because:

• Neurological damage can occur at serum levels of 200–400 pg/mL, especially in elderly patients
• The "normal range" was historically derived from small populations and does not distinguish between biologically active and inactive B12
• MMA and homocysteine can be elevated — indicating functional deficiency — even when serum B12 is in the low-normal range (200–400 pg/mL)
• Japan and some European countries use a lower limit of 500–550 pg/mL for their normal ranges

Holotranscobalamin (active B12): Holotranscobalamin (holoTC) measures only the 20% of serum B12 bound to transcobalamin II — the fraction available for cellular uptake. It is a more accurate early marker of depletion than total serum B12. A holotranscobalamin below 35 pmol/L indicates deficiency. This test is increasingly available but not yet standard in most clinical laboratories.

A practical approach for borderline cases: if serum B12 is 200–400 pg/mL with compatible symptoms or risk factors, measure MMA and homocysteine. If either is elevated, a therapeutic trial of B12 supplementation is warranted. Response to treatment (improvement in symptoms, normalization of MMA/homocysteine) confirms functional deficiency.

Treatment

Intramuscular Injections

Cyanocobalamin 1000 µg IM daily for 7 days, then weekly for 4 weeks, then monthly is the standard regimen for severe deficiency, pernicious anemia, or malabsorption-related deficiency. Hydroxocobalamin is preferred in the UK and some European countries due to its longer half-life (retained longer in tissues). Neurological symptoms may take months to fully resolve; improvement is more likely if treatment begins within the first year of symptom onset.

High-Dose Oral Supplementation

High-dose oral B12 (1000–2000 µg/day) is effective even in pernicious anemia because approximately 1% of B12 is absorbed by passive diffusion throughout the intestinal mucosa, independent of intrinsic factor. Multiple randomized trials have shown oral and IM treatment to be equally effective in correcting serum levels and hematologic parameters. However, IM remains preferred for neurological presentations and patients with severe malabsorption. Sublingual and intranasal formulations are available as alternatives.

Maintenance and Prevention

• Dietary adequacy: The RDA is 2.4 µg/day for adults; higher during pregnancy (2.6 µg/day) and lactation (2.8 µg/day). Animal foods provide ample B12 for omnivores.
• Vegans and vegetarians: Regular B12 supplementation or consumption of fortified foods is non-negotiable. Fortified nutritional yeast (not brewer's yeast) is a reliable dietary source for vegans.
• Metformin users: Consider periodic B12 monitoring and supplementation, especially in those with borderline levels or neuropathy symptoms.
• Post-bariatric patients: Lifelong supplementation with doses higher than standard multivitamins; many bariatric programs use 350–500 µg/day sublingual or oral cyanocobalamin or monthly IM injections.
• Elderly patients: Crystalline B12 supplements (not food-bound B12) bypass the food-protein digestion step impaired by atrophic gastritis; a standard multivitamin providing 25–100 µg/day is generally sufficient.

References

1. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–160.
2. Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014;349:g5226.
3. Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. How prevalent is vitamin B(12) deficiency among vegetarians? Nutr Rev. 2013;71(2):110–117.
4. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761.
5. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–2442.
6. Hvas AM, Nexo E. Diagnosis and treatment of vitamin B12 deficiency: an update. Haematologica. 2006;91(11):1506–1512.
7. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50(1):3–32.
8. Andrès E, Loukili NH, Noel E, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004;171(3):251–259.
9. Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood. 2008;112(6):2214–2221.
10. Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Mol Nutr Food Res. 2015;59(7):1364–1372.
11. Dali-Youcef N, Andrès E. An update on cobalamin deficiency in adults. QJM. 2009;102(1):17–28.
12. Nilsson M, Norberg B, Hultdin J, Sandström H, Westman G, Lövheim H. Medical intelligence: vitamin B12: oral compared with intramuscular administration. Postgrad Med J. 2005;81(953):191–193.

Back to Table of Contents